Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Nov 08, 2023

SELL
$0.57 - $1.08 $118,046 - $223,668
-207,100 Reduced 10.99%
1,676,684 $1.01 Million
Q2 2023

Aug 14, 2023

SELL
$0.57 - $1.08 $118,046 - $223,668
-207,100 Reduced 10.99%
1,676,684 $1.01 Million
Q1 2023

Nov 08, 2023

BUY
$0.66 - $1.29 $1.03 Million - $2 Million
1,553,560 Added 470.46%
1,883,784 $1.41 Million
Q1 2023

May 15, 2023

BUY
$0.66 - $1.29 $1.03 Million - $2 Million
1,553,560 Added 470.46%
1,883,784 $1.41 Million
Q4 2022

Nov 08, 2023

SELL
$1.1 - $2.45 $1.71 Million - $3.82 Million
-1,557,775 Reduced 82.51%
330,224 $409,000
Q4 2022

Feb 14, 2023

SELL
$1.1 - $2.45 $1.71 Million - $3.82 Million
-1,557,775 Reduced 82.51%
330,224 $409,000
Q3 2022

Nov 08, 2023

BUY
$1.96 - $3.32 $1.48 Million - $2.51 Million
757,238 Added 66.97%
1,887,999 $3.89 Million
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.32 $1.48 Million - $2.51 Million
757,238 Added 66.97%
1,887,999 $3.89 Million
Q2 2022

Nov 08, 2023

SELL
$2.27 - $4.86 $1.24 Million - $2.65 Million
-545,923 Reduced 32.56%
1,130,761 $3.13 Million
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $2.57 Million - $5.5 Million
1,130,761 New
1,130,761 $3.13 Million
Q3 2021

Nov 15, 2021

SELL
$5.54 - $7.51 $3.14 Million - $4.26 Million
-566,942 Closed
0 $0
Q2 2021

Nov 08, 2023

SELL
$7.78 - $11.4 $3.73 Million - $5.46 Million
-479,187 Reduced 45.81%
566,942 $4.82 Million
Q2 2021

Aug 16, 2021

SELL
$7.78 - $11.4 $3.73 Million - $5.46 Million
-479,187 Reduced 45.81%
566,942 $4.82 Million
Q1 2021

Nov 08, 2023

BUY
$5.12 - $8.48 $416,880 - $690,458
81,422 Added 8.44%
1,046,129 $8.27 Million
Q1 2021

May 13, 2021

BUY
$5.12 - $8.48 $416,880 - $690,458
81,422 Added 8.44%
1,046,129 $8.28 Million
Q4 2020

Nov 08, 2023

SELL
$3.16 - $7.03 $2.25 Million - $5.01 Million
-711,977 Reduced 42.46%
964,707 $5.61 Million
Q4 2020

Feb 16, 2021

SELL
$3.16 - $7.03 $887,173 - $1.97 Million
-280,751 Reduced 22.54%
964,707 $5.62 Million
Q3 2020

Nov 08, 2023

BUY
$3.26 - $4.73 $986,048 - $1.43 Million
302,469 Added 32.08%
1,245,458 $4.22 Million
Q3 2020

Nov 13, 2020

BUY
$3.26 - $4.73 $986,048 - $1.43 Million
302,469 Added 32.08%
1,245,458 $4.22 Million
Q2 2020

Nov 08, 2023

BUY
$1.58 - $4.63 $603,858 - $1.77 Million
382,189 Added 68.15%
942,989 $4.36 Million
Q2 2020

Aug 13, 2020

BUY
$1.58 - $4.63 $603,858 - $1.77 Million
382,189 Added 68.15%
942,989 $4.35 Million
Q1 2020

Nov 08, 2023

SELL
$1.44 - $3.02 $427,638 - $896,852
-296,971 Reduced 34.62%
560,800 $886,000
Q1 2020

May 13, 2020

SELL
$1.44 - $3.02 $427,638 - $896,852
-296,971 Reduced 34.62%
560,800 $886,000
Q4 2019

Nov 08, 2023

BUY
$2.25 - $3.07 $1.21 Million - $1.64 Million
535,600 Added 166.25%
857,771 $2.35 Million
Q4 2019

Feb 13, 2020

BUY
$2.25 - $3.07 $1.21 Million - $1.64 Million
535,600 Added 166.25%
857,771 $2.35 Million
Q1 2019

Nov 08, 2023

SELL
$3.05 - $4.34 $41,489 - $59,037
-13,603 Reduced 4.05%
322,171 $1.35 Million
Q1 2019

May 14, 2019

SELL
$3.05 - $4.34 $41,489 - $59,037
-13,603 Reduced 4.05%
322,171 $1.35 Million
Q4 2018

Nov 08, 2023

SELL
$2.82 - $4.67 $273,407 - $452,770
-96,953 Reduced 22.41%
335,774 $1.04 Million
Q4 2018

Feb 13, 2019

SELL
$2.82 - $4.67 $273,407 - $452,770
-96,953 Reduced 22.41%
335,774 $1.04 Million
Q3 2018

Nov 08, 2023

BUY
$1.45 - $6.15 $66,504 - $282,069
45,865 Added 11.86%
432,727 $1.88 Million
Q3 2018

Nov 14, 2018

BUY
$1.45 - $6.15 $66,504 - $282,069
45,865 Added 11.86%
432,727 $1.88 Million
Q1 2018

Nov 08, 2023

SELL
$1.25 - $2.65 $1.61 Million - $3.42 Million
-1,289,822 Reduced 76.93%
386,862 $716 Million
Q1 2018

May 14, 2018

BUY
$1.25 - $2.65 $483,577 - $1.03 Million
386,862 New
386,862 $716,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.